232 related articles for article (PubMed ID: 34098955)
21. Stopping
Moore WC; Kornmann O; Humbert M; Poirier C; Bel EH; Kaneko N; Smith SG; Martin N; Gilson MJ; Price RG; Bradford ES; Liu MC
Eur Respir J; 2022 Jan; 59(1):. PubMed ID: 34172470
[TBL] [Abstract][Full Text] [Related]
22. Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes.
Prazma CM; Idzko M; Douglass JA; Bourdin A; Mallett S; Albers FC; Yancey SW
J Asthma Allergy; 2021; 14():675-683. PubMed ID: 34163180
[TBL] [Abstract][Full Text] [Related]
23. Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab.
Li L; Wang Z; Cui L; Xu Y; Guan K; Zhao B
Clin Transl Allergy; 2021 Jun; 11(4):e12038. PubMed ID: 34123366
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of Switching Biologics for Severe Asthma Patients in Japan: A Single-Center Retrospective Study.
Numata T; Araya J; Miyagawa H; Okuda K; Fujita Y; Utsumi H; Takekoshi D; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Kuwano K
J Asthma Allergy; 2021; 14():609-618. PubMed ID: 34113131
[TBL] [Abstract][Full Text] [Related]
25. Biologic Therapies for Allergic Rhinitis and Nasal Polyposis.
Geng B; Dilley M; Anterasian C
Curr Allergy Asthma Rep; 2021 Jun; 21(6):36. PubMed ID: 34110505
[TBL] [Abstract][Full Text] [Related]
26. Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO.
Pavord ID; Chapman KR; Bafadhel M; Sciurba FC; Bradford ES; Schweiker Harris S; Mayer B; Rubin DB; Yancey SW; Paggiaro P
Int J Chron Obstruct Pulmon Dis; 2021; 16():1755-1770. PubMed ID: 34163157
[TBL] [Abstract][Full Text] [Related]
27. High serum cytokine levels may predict the responsiveness of patients with severe asthma to benralizumab.
Watanabe S; Suzukawa M; Tashimo H; Ohshima N; Asari I; Imoto S; Kobayashi N; Tohma S; Nagase T; Ohta K
J Asthma; 2022 Aug; 59(8):1604-1612. PubMed ID: 34121592
[TBL] [Abstract][Full Text] [Related]
28. From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases.
Pavord ID; Bel EH; Bourdin A; Chan R; Han JK; Keene ON; Liu MC; Martin N; Papi A; Roufosse F; Steinfeld J; Wechsler ME; Yancey SW
Allergy; 2022 Mar; 77(3):778-797. PubMed ID: 34402066
[TBL] [Abstract][Full Text] [Related]
29. Airway gene expression identifies subtypes of type 2 inflammation in severe asthma.
Frøssing L; Silberbrandt A; Von Bülow A; Kjaersgaard Klein D; Ross Christensen M; Backer V; Baines KJ; Porsbjerg C
Clin Exp Allergy; 2022 Jan; 52(1):59-69. PubMed ID: 34142396
[TBL] [Abstract][Full Text] [Related]
30. Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma.
Kraft M; Brusselle G; FitzGerald JM; Pavord ID; Keith M; Fagerås M; Garcia Gil E; Hirsch I; Goldman M; Colice G
Eur Respir J; 2021 Dec; 58(6):. PubMed ID: 34112734
[TBL] [Abstract][Full Text] [Related]
31. Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease.
Buchheit KM; Lewis E; Gakpo D; Hacker J; Sohail A; Taliaferro F; Berreondo Giron E; Asare C; Vukovic M; Bensko JC; Dwyer DF; Shalek AK; Ordovas-Montanes J; Laidlaw TM
J Allergy Clin Immunol; 2021 Aug; 148(2):574-584. PubMed ID: 34144111
[TBL] [Abstract][Full Text] [Related]
32. Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months.
Kayser MZ; Drick N; Milger K; Fuge J; Kneidinger N; Korn S; Buhl R; Behr J; Welte T; Suhling H
J Asthma Allergy; 2021; 14():863-871. PubMed ID: 34285513
[TBL] [Abstract][Full Text] [Related]
33. Treatment of lymphocyte-variant hypereosinophilic syndrome (L-HES): what to consider after confirming the elusive diagnosis.
Williams AK; Dou C; Chen LYC
Br J Haematol; 2021 Dec; 195(5):669-680. PubMed ID: 34105142
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness analysis of anti-IL-5 therapies of severe eosinophilic asthma in Spain.
González-Barcala FJ; Muñoz-Gall X; Mariscal E; García A; Yang S; van de Wetering G; Izquierdo-Alonso JL
J Med Econ; 2021; 24(1):874-882. PubMed ID: 34114935
[TBL] [Abstract][Full Text] [Related]
35. Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide.
Couillard S; Laugerud A; Jabeen M; Ramakrishnan S; Melhorn J; Hinks T; Pavord I
Thorax; 2022 Feb; 77(2):199-202. PubMed ID: 34362839
[TBL] [Abstract][Full Text] [Related]
36. Reduction/elimination of blood eosinophils in severe asthma: should there be a safety consideration?
Katsoulis K; Kipourou M; Loukides S
Expert Opin Biol Ther; 2022 Mar; 22(3):377-384. PubMed ID: 34328380
[TBL] [Abstract][Full Text] [Related]
37. Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study.
Gleich GJ; Roufosse F; Chupp G; Faguer S; Walz B; Reiter A; Yancey SW; Bentley JH; Steinfeld J;
J Allergy Clin Immunol Pract; 2021 Dec; 9(12):4431-4440.e1. PubMed ID: 34389506
[TBL] [Abstract][Full Text] [Related]
38. Oral Corticosteroids Dependence and Biologic Drugs in Severe Asthma: Myths or Facts? A Systematic Review of Real-World Evidence.
Calzetta L; Aiello M; Frizzelli A; Bertorelli G; Rogliani P; Chetta A
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281184
[TBL] [Abstract][Full Text] [Related]
39. Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case series.
Detoraki A; Tremante E; Poto R; Morelli E; Quaremba G; Granata F; Romano A; Mormile I; Rossi FW; de Paulis A; Spadaro G
Respir Res; 2021 Jun; 22(1):185. PubMed ID: 34162391
[TBL] [Abstract][Full Text] [Related]
40. Hypersensitivity reactions to biologicals: An EAACI position paper.
Bavbek S; Pagani M; Alvarez-Cuesta E; Castells M; Dursun AB; Hamadi S; Madrigal-Burgaleta R; Sanchez-Sanchez S; Vultaggio A
Allergy; 2022 Jan; 77(1):39-54. PubMed ID: 34157134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
